These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7138842)

  • 1. [25-oxindolylalanine]glucagon and [27-methionine sulfoxide]glucagon: preparation, purification, and characterization.
    Coolican SA; Jones BN; England RD; Flanders KC; Condit JD; Gurd RS
    Biochemistry; 1982 Sep; 21(20):4974-81. PubMed ID: 7138842
    [No Abstract]   [Full Text] [Related]  

  • 2. Photoaffinity labeling of the glucagon receptor with a new glucagon analog.
    Wright DE; Horuk R; Rodbell M
    Eur J Biochem; 1984 May; 141(1):63-7. PubMed ID: 6327311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon carboxyl-terminal derivatives: preparation, purification, and characterization.
    England RD; Jones BN; Flanders KC; Coolican SA; Rothgeb TM; Gurd RS
    Biochemistry; 1982 Mar; 21(5):940-50. PubMed ID: 7074063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of 2-thioltryptophan-glucagon and (tryptophan-S-glucagon)2. Differences in binding to the glucagon receptor in the hepatic adenylate cyclase system.
    Wright DE; Rodbell M
    J Biol Chem; 1980 Nov; 255(22):10884-7. PubMed ID: 7430160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of specific trinitrophenylation of the lysine epsilon amino group of glucagon on receptor binding and adenylate cyclase activation.
    Liepnieks JJ; Epand RM
    Arch Biochem Biophys; 1983 Aug; 225(1):102-9. PubMed ID: 6311099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and isolation of a glucagon antagonist.
    Bregman MD; Hruby VJ
    FEBS Lett; 1979 May; 101(1):191-4. PubMed ID: 446735
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs.
    Andreu D; Merrifield RB
    Eur J Biochem; 1987 May; 164(3):585-90. PubMed ID: 3032623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic activity and conformational properties of glucagon and glucagon analogs.
    Epand RM; Cote TE; Hoa DH; Rosselin G; Schreier S
    Metabolism; 1976 Nov; 25(11 Suppl 1):1317-8. PubMed ID: 185490
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormone receptors. I. Activation of rat liver plasma membrane adenylyl cyclase and fat cell lipolysis by agarose-glucagon.
    Johnson CB; Blecher M; Giorgio NA
    Biochem Biophys Res Commun; 1972 Feb; 46(3):1035-41. PubMed ID: 5012158
    [No Abstract]   [Full Text] [Related]  

  • 10. Methylation of glucagon, characterization of the sulfonium derivative, and regeneration of the native covalent structure.
    Rothgeb TM; Jones BN; Hayes DF; Gurd RS
    Biochemistry; 1977 Dec; 16(26):5813-8. PubMed ID: 588556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubilization of glucagon and epinephrine sensitive adenylate cyclase from rat liver plasma membranes.
    Ryan J; Storm DR
    Biochem Biophys Res Commun; 1974 Sep; 60(1):304-11. PubMed ID: 4418132
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipolytic and adenyl-cyclase-stimulating activity of N alpha-trinitrophenyl glucagon: comparison with other glucagon derivatives modified at the amino terminus.
    Jean-Baptiste E; Rizack MA; Epand RM
    Biosci Rep; 1982 Mar; 2(3):163-7. PubMed ID: 7066487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential acid stabilities of citraconylated amino groups of glucagon. Preparation of N alpha-citraconyl glucagon and evaluation of its biological properties.
    Liepnieks JJ; Epand RM
    Biochim Biophys Acta; 1982 Oct; 707(2):171-7. PubMed ID: 6291617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and properties of glucagon analogs prepared by semi-synthesis from CNBr-glucagon.
    Wright DE; Hruby VJ; Rodbell M
    Biochim Biophys Acta; 1980 Aug; 631(1):49-58. PubMed ID: 6249392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal polypeptide and glucagon: stimulation of adenylate cyclase activity via distinct receptors in liver and fat cell membranes.
    Desbuguois B; Laudat MH; Laudat P
    Biochem Biophys Res Commun; 1973 Aug; 53(4):1187-94. PubMed ID: 4356054
    [No Abstract]   [Full Text] [Related]  

  • 16. Re-evaluation of glucagon1-6: the N-terminal hexapeptide of glucagon is not biologically active in the hepatic adenylate cyclase system.
    Pelton JT; Trivedi D; Hruby VJ
    Life Sci; 1983 Sep; 33(13):1307-14. PubMed ID: 6888179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-stimulable adenylyl cyclase in rat liver. Effects of chronic uremia and intermittent glucagon administration.
    Dighe RR; Rojas FJ; Birnbaumer L; Garber AJ
    J Clin Invest; 1984 Apr; 73(4):1004-12. PubMed ID: 6323531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon structure and function. II. Increased activity of iodoglucagon.
    Bromer WW; Boucher ME; Patterson JM
    Biochem Biophys Res Commun; 1973 Jul; 53(1):134-9. PubMed ID: 4741542
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of amidinated glucagons.
    Wright DE; Rodbell M
    Eur J Biochem; 1980 Oct; 111(1):11-6. PubMed ID: 7439177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.